Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMVM13R)

Drug Name
LJPC-401 Drug Info
Indication
Disease Entry ICD 11 Status REF
Beta thalassemia 3A50.2 Phase 2 [1]
Hemochromatosis 5C64.1Y Phase 2 [2]
Cross-matching ID
TTD Drug ID
DMVM13R

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Hepcidin (HAMP) TTPCG5T HEPC_HUMAN Agonist [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Hepcidin (HAMP) DTT HAMP 10.14 3.018 4.372 4.315
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Beta thalassemia
ICD Disease Classification 3A50.2
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Hepcidin (HAMP) DTT HAMP 5.37E-01 0.18 0.47
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT03381833) A Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Adult Patients With Transfusion-Dependent Beta Thalassemia. U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT03395704) A Study of LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis. U.S. National Institutes of Health.